Where can I buy Pemetinib/Pemetinib in the country?

Pemigatinib is an oral anticancer drug that has attracted much attention in the field of targeted therapy in recent years. It is mainly suitable for the treatment of patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. Its mechanism is based on precise inhibition of fibroblast growth factor receptors, thereby blocking abnormal signaling chains and inhibiting the proliferation and spread of tumor cells. Especially in diseases such as cholangiocarcinoma, for which traditional treatments are limited, the emergence of pemetinib provides new treatment options for some patients carrying specific genetic mutations, and also marks that targeted therapy is gradually moving toward more rare and complex tumor types.

In the domestic market, pemetinib has been approved by the State Food and Drug Administration in the form of "pemetinib tablets" in 2023. The indications are consistent with those internationally, that is, for patients with cholangiocarcinoma diagnosed with FGFR2 fusion or rearrangement. Currently, the commercially available specifications include 4.5 mg 14 tablets and 9 mg 14 tablets. It is usually recommended to adjust the dosage in stages according to the doctor's prescription. Due to its high R&D and import costs, and the fact that it has not yet been included in the national medical insurance catalog, the current market price of the drug is relatively expensive, with each box usually selling for between 20,000 and 50,000 yuan.

Patients in China can obtain pemetinib through a variety of formal channels, including oncology pharmacies in some tertiary hospitals, authorized hospital platforms, and specialty drug channels that cooperate with drug import companies. Some provinces and cities have also launched charitable assistance projects or commercial insurance auxiliary plans to help patients reduce their financial burden. However, overall, there is still a certain threshold for access, especially for patients in grassroots areas, and accessibility needs to be improved.

It should be noted that pemetinib is a "precision gene targeting drug" and requires FGFR2-related gene fusion testing before use. It is recommended that patients undergo molecular typing at a professional medical institution before deciding whether to initiate treatment. For patients who have been diagnosed with cholangiocarcinoma and have a clear target, pemetinib is one of the few treatment options with a clear target effect and has important clinical significance.

Reference materials:https://go.drugbank.com/drugs/DB15102